Get the Stockscreener App
223.43
2.01%
4.41
After Hours:
222.03
-1.40
-0.63%
Overview
News
Price History
Option Chain
Financials
Why ABBV Down?
Discussions
Forecast
Dividend History
Abbvie Inc stock is traded at $223.43, with a volume of 6.05M.
It is up +2.01% in the last 24 hours and down -0.22% over the past month.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
See More
Previous Close:
$219.02
Open:
$218.75
24h Volume:
6.05M
Relative Volume:
0.95
Market Cap:
$394.89B
Revenue:
$61.16B
Net Income/Loss:
$4.20B
P/E Ratio:
94.39
EPS:
2.3671
Net Cash Flow:
$19.68B
1W Performance:
+0.19%
1M Performance:
-0.22%
6M Performance:
+13.82%
1Y Performance:
+15.78%
1-Day Range:
$218.50
$225.82
1-Week Range:
$204.27
$229.78
52-Week Range:
$164.39
$244.81
Abbvie Inc Stock (ABBV) Company Profile
Name
Abbvie Inc
Sector
Industry
Phone
(847) 932-7900
Address
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV vs LLY, JNJ, MRK, AZN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
223.43 | 387.09B | 61.16B | 4.20B | 19.68B | 2.3671 |
|
LLY
Lilly Eli Co
|
1,058.18 | 913.67B | 65.18B | 20.64B | 6.44B | 22.96 |
|
JNJ
Johnson Johnson
|
239.99 | 572.91B | 94.19B | 26.80B | 20.46B | 11.05 |
|
MRK
Merck Co Inc
|
121.93 | 297.22B | 65.00B | 18.26B | 13.05B | 7.2751 |
|
AZN
Astrazeneca Plc
|
193.03 | 290.15B | 58.07B | 9.40B | 9.87B | 3.0115 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-08-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-10-25 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-04-25 | Downgrade | DZ Bank | Buy → Hold |
| Oct-14-25 | Downgrade | Erste Group | Buy → Hold |
| Oct-01-25 | Downgrade | HSBC Securities | Buy → Hold |
| Sep-17-25 | Upgrade | Berenberg | Hold → Buy |
| Aug-12-25 | Resumed | Piper Sandler | Overweight |
| Aug-07-25 | Upgrade | Daiwa Securities | Neutral → Outperform |
| May-14-25 | Downgrade | Citigroup | Buy → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-05-24 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Nov-22-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-04-24 | Upgrade | Argus | Hold → Buy |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jun-05-24 | Upgrade | HSBC Securities | Hold → Buy |
| May-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-29-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-18-23 | Downgrade | HSBC Securities | Buy → Hold |
| Dec-11-23 | Upgrade | Goldman | Neutral → Buy |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-30-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Resumed | UBS | Neutral |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| Jul-25-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-05-23 | Downgrade | Argus | Buy → Hold |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Feb-22-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-10-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Nov-08-22 | Downgrade | Societe Generale | Buy → Hold |
| Aug-01-22 | Downgrade | Atlantic Equities | Overweight → Neutral |
| May-23-22 | Initiated | SVB Leerink | Underperform |
| May-06-22 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Feb-28-22 | Downgrade | UBS | Buy → Neutral |
| Feb-03-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-03-22 | Reiterated | Barclays | Equal Weight |
| Feb-03-22 | Reiterated | BofA Securities | Neutral |
| Feb-03-22 | Reiterated | Goldman | Neutral |
| Jan-13-22 | Initiated | Redburn | Buy |
| Jan-12-22 | Reiterated | BMO Capital Markets | Outperform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Nov-23-21 | Upgrade | Societe Generale | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-23-20 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Jun-09-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jun-02-20 | Upgrade | Argus | Hold → Buy |
| May-18-20 | Resumed | BofA/Merrill | Neutral |
| May-12-20 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-20 | Resumed | Morgan Stanley | Overweight |
| Apr-20-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-26-19 | Reiterated | Cowen | Outperform |
| Sep-26-19 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-27-19 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jun-26-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-28-19 | Initiated | Goldman | Neutral |
| Apr-29-19 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
View All
Abbvie Inc Stock (ABBV) Latest News
DOJ Drops Challenge To AbbVie's $1.6B Break Fee Deduction - Law360
AbbVie stock price closes higher on Moody’s upgrade — what ABBV bulls and bears watch next - TechStock²
Lupin and AbbVie Announce Partnership to Develop and Commercialize Novel Oncology Drug to treat Hematological CancersLupin | Press Release - lupin.com
Earnings Scorecard: 22 out of 23 healthcare firms deliver EPS wins this week - Seeking Alpha
AbbVie stock price: ABBV ends week near $223 after earnings swing — what to watch next - TechStock²
AbbVie (ABBV) Receives a Buy from Guggenheim - The Globe and Mail
CVS Caremark Replaces Amgen And Eli Lilly's Branded Drugs, Expands Biosimilar Strategy For Weak Bone Disorder - Benzinga
AbbVie upgraded by Moody’s to A2 with stable outlook - Investing.com Nigeria
Bank of America Securities Keeps Their Hold Rating on AbbVie (ABBV) - The Globe and Mail
Cantor Fitzgerald reiterates Overweight rating on AbbVie stock - Investing.com
Evercore ISI Group Lowers Price Target for AbbVie (ABBV) to $228 - GuruFocus
(02/06/26) Top Picks 2026: AbbVie Inc. (ABBV) - moneyshow.com
AbbVie Earnings Call: New Growth Engines Take Lead - The Globe and Mail
AbbVie stock ticks higher after hours as traders digest 2026 outlook after Rinvoq miss - TechStock²
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Boston Scientific (BSX) - The Globe and Mail
Earnings roundup: AbbVie angst, a bifurcated vaccine market and Bristol Myers’ waiting game - BioPharma Dive
Evercore ISI Adjusts Price Target on AbbVie to $228 From $232, Maintains Outperform Rating - marketscreener.com
Goldman Sachs Adjusts Price Target on AbbVie to $240 From $223, Maintains Neutral Rating - marketscreener.com
AbbVie's Prognosis: The February Dip Looks Like a Buy Signal - Finviz
AbbVie’s Prognosis: The February Dip Looks Like a Buy Signal - The Globe and Mail
AbbVie (ABBV) Receives a Neutral Rating as UBS Lowers Price Targ - GuruFocus
UBS Adjusts AbbVie Price Target to $230 From $240, Maintains Neutral Rating - marketscreener.com
AbbVie Submits Regulatory Applications for Rinvoq in Patients with Vitiligo - Contract Pharma
AbbVie: The Market Is Getting It Wrong - Seeking Alpha
AbbVie Inc. (NYSE:ABBV) Q4 2025 Earnings Call Transcript - Insider Monkey
AbbVie shares slide on perceived Humira reliance - The Pharma Letter
AbbVie Shares Fall as Wall Street Focuses on Filler Weakness - The Business of Fashion
ABBV Q4 Deep Dive: Immunology and Neuroscience Growth Offset Aesthetics Softness and Pricing Headwinds - Finviz
Street View: AbbVie's strong drug pipeline sets it up well for long‑term growth - TradingView
AbbVie: Skyrizi And Rinvoq Growth Isn't Everything But It's A Lot (NYSE:ABBV) - Seeking Alpha
AbbVie Earnings: Skyrizi Holds Steady Share Despite Competition - morningstar.com
AbbVie Inc. (ABBV) Shares Slide as Revenue Beat and Raised 2026 Outlook Fail to Stem Sell-Off - AlphaStreet News -
Clear Street says AbbVie move further validates Oruka Therapeutics’ strategy - TipRanks
AbbVie Beats on Q4 Earnings, Stock Down Despite Upbeat '26 View - The Globe and Mail
AbbVie Q4 Earnings Call Highlights - Yahoo Finance
AbbVie: Double-Digit Growth For Immunology Products Continues With HUMIRA Surprise (ABBV) - Seeking Alpha
AbbVie Q4 Earnings Review: I May Have Just Made A Huge Mistake (NYSE:ABBV) - Seeking Alpha
AbbVie’s Deal Focus Is Not Just Early-Stage Assets - Citeline News & Insights
ABBV AbbVie Inc. Feb 2026 Evercore Maintains Outperform, PT lowered to $228 - Meyka
AbbVie Inc (ABBV) Q4 2025 Earnings Call Highlights: Record Reven - GuruFocus
AMD, AbbVie, Boston Scientific, Eli Lilly, MP, Super Micro, Palantir, and More Movers - Barron's
AbbVie forecasts upbeat 2026 profit, but shares fall on key drug’s sales miss - WTVB
AbbVie’s Rinvoq Vitiligo Bid Raises Questions On Growth And Valuation - Yahoo Finance
AbbVie's Immunology Fortress Can’t Hide Cracks In Diversification (Downgrade) (NYSE:ABBV) - Seeking Alpha
AbbVie Buy Thesis Anchored by Robust Immunology Momentum, Neurology Upside, and Long-Term IBD Defense - TipRanks
AbbVie stock drops after Rinvoq sales miss, even as 2026 profit forecast tops estimates - TechStock²
AbbVie Earnings Beat Wall Street Expectations. The Stock Is Falling Anyway. - Barron's
AbbVie forecasts 9.5% sales growth in 2026 amid blockbuster launches and pipeline momentum - MSN
AbbVie stock slides as investors focus on weakness in the aesthetics business - Crain's Chicago Business
AbbVie nears five-month low as Humira drives Q4 beat, not Rinvoq - Seeking Alpha
AMD, AbbVie, Lilly, Boston Scientific, MP Materials, Super Micro, Silicon Labs, Uber, and More Movers - Barron's
Abbvie Inc Stock (ABBV) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):